Evidence map›Paper›PMID 22411420›Full record

ArticleJournal of urban health : bulletin of the New York Academy of Medicine2012

Estimates of the population prevalence of injection drug users among hispanic residents of large US metropolitan areas.

Enrique R Pouget, Samuel R Friedman, Charles M Cleland, Barbara Tempalski, Hannah L F Cooper

Erratum issuedOpen access · bronzeAbstract read
In one paragraph

Article in Journal of urban health : bulletin of the New York Academy of Medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Epidemiology of Injection Drug Use: New Trends and Prominent Issues.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2016
    Review
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Enrique R PougetNational Development and Research Institutes, Inc., New York, NY, USA. pouget@ndri.org
Samuel R Friedman
Charles M Cleland
Barbara Tempalski
Hannah L F Cooper
National Development and Research Institutes · USEmory University · USNew York University · US

Funding

COMMUNITY VULNERABILITY AND RESPONSES TO IDU-RELATED HIVR01DA013336 · NIDA · NATIONAL DEVELOPMENT &RES INSTITUTES · PI COOPER, HANNAH LF, FRIEDMAN, SAMUEL R · 2000 to 2013
$7.6M
Synthesis: HCV Epidemiology and Prevention in Drug UsersR01DA018609 · NIDA · NATIONAL DEVELOPMENT &RES INSTITUTES · PI HAGAN, HOLLY C. · 2004 to 2006
$1.3M
NIDA NIH HHS P30 DA121041NIDA NIH HHS R01 DA013336NIDA NIH HHS R01DA013336NIDA NIH HHS R01 DA018609
6 · The paper itself

Abstract

Little information exists on the population prevalence or geographic distribution of injection drug users (IDUs) who are Hispanic in the USA. Here, we present yearly estimates of IDU population prevalence among Hispanic residents of the 96 most populated US metropolitan statistical areas (MSAs) for 1992-2002. First, yearly estimates of the proportion of IDUs who were Hispanic in each MSA were created by combining data on (1) IDUs receiving drug treatment services in Substance Abuse and Mental Health Services Administration (SAMHSA)'s Treatment Entry Data System, (2) IDUs being tested in the Centers for Disease Control and Prevention (CDC) HIV-Counseling and Testing System, and (3) incident AIDS diagnoses among IDUs, supplemented by (4) data on IDUs who were living with AIDS. Then, the resulting proportions were multiplied by published yearly estimates of the number of IDUs of all racial/ethnic groups in each MSA to produce Hispanic IDU population estimates. These were divided by Hispanic population data to produce population prevalence rates. Time trends were tested using mixed-effects regression models. Hispanic IDU prevalence declined significantly on average (1992 mean = 192, median = 133; 2002 mean = 144, median = 93; units are per 10,000 Hispanics aged 15-64). The highest prevalence rates across time tended to be in smaller northeastern MSAs. Comparing the last three study years to the first three, prevalence decreased in 82% of MSAs and increased in 18%. Comparisons with data on drug-related mortality and hepatitis C mortality supported the validity of the estimates. Generally, estimates of Hispanic IDU population prevalence were higher than published estimates for non-Hispanic White residents and lower than published estimates for non-Hispanic Black residents. Further analysis indicated that the proportion of IDUs that was Hispanic decreased in 52% and increased in 48% of MSAs between 2002 and 2007. The estimates resulting from this study can be used to investigate MSA-level social and economic factors that may have contributed to variations across MSAs and to help guide prevention program planning for Hispanic IDUs within MSAs. Future research should attempt to determine to what extent these trends are applicable to Hispanic national origin subgroups.

Indexed as

Acquired Immunodeficiency SyndromeAdolescentAdultBlack or African AmericanBlack PeopleCenters for Disease Control and Prevention, U.S.Data CollectionHepatitis CHispanic or LatinoHumansMiddle AgedNew EnglandPrevalenceReproducibility of ResultsSubstance Abuse, IntravenousUnited States

Identifiers

PMID22411420
PMCPMC3368042
OpenAlexW2033716416

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.